禾元生物：创新实现“稻米造血” 努力打造世界一流生物医药公司——武汉禾元生物科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放

Company Overview - The company is an innovative biopharmaceutical enterprise with a globally leading plant bioreactor technology platform, specifically a rice endosperm cell bioreactor expression system [1][3] - The company has developed multiple products including drugs, pharmaceutical excipients, and research reagents based on its rice endosperm cell bioreactor expression system [1] Product Pipeline - As of now, the company has a total of 8 drug candidates in its pipeline, with the fastest progressing product, recombinant human albumin injection (OsrHSA, HY1001), expected to receive approval by July 2025 for the indication of "hypoalbuminemia due to liver cirrhosis" [2] - Five products are currently in clinical trials, while several others are in preclinical research stages [2] Core Technology - The company has established an internationally leading rice endosperm cell bioreactor expression system, which includes upstream and downstream technologies for efficient recombinant protein expression and purification [3] Production Capacity - The company has built a commercial-scale production line capable of producing 10 tons of OsrHSA raw liquid annually and 1 million dosage forms, with a cGMP intelligent production line [4] - A new production line with a capacity of 120 tons of OsrHSA raw liquid is under construction, expected to be completed by September 2024 [4] Intellectual Property - The company holds a total of 21 domestic invention patents and 62 foreign invention patents [4] Research and Development - The company has strong research capabilities, having independently or led 3 national major science and technology projects and 2 provincial key projects [5] - The company has published 20 SCI papers and books related to its core technologies and products [5] Awards and Recognition - The company's core technology has received national awards, including the Second Prize of National Science and Technology Invention and an Excellent Patent Award from the National Intellectual Property Administration [6] Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was 13.40 million, 24.26 million, 25.22 million, and 12.71 million respectively [7] - Research and development expenses for the same periods were 110.50 million, 159.10 million, 116.79 million, and 55.94 million, indicating significant investment in R&D [8] Development Strategy - The company aims to provide green, safe, accessible, and sufficient biopharmaceutical products globally, focusing on unmet clinical needs and leveraging its technological advantages [9] Competitive Advantages - The company’s main competitive advantages include its ideal recombinant protein drug preparation platform, a large potential market for recombinant human albumin, and the safety and environmental benefits of its products [10] Industry Characteristics - The biopharmaceutical industry is characterized by interdisciplinary applications, continuous technological iteration, long R&D cycles, high investment, and regulatory barriers [15] Market Demand - The clinical demand for human serum albumin drugs in China is significant, with a market size projected to grow from 25.8 billion in 2020 to 57 billion by 2030 [16] Future Innovations - The company plans to focus on original innovations in rice endosperm cell expression technology, accelerate the development of long-acting drugs based on recombinant human albumin, and advance multiple therapeutic recombinant biological products [14]